CellSeed Inc. is a regenerative medicine company established in 2001 spinning off from Institute of Advanced BioMedical Engineering and Science (ABMES), Tokyo Women's Medical University (TWMU). CellSeed Inc. provides clinical stage cell sheet-based regenerative medicine products (ATMP) and proprietary cell culture-ware invented by Professor Teruo Okano. The proprietary culture-ware, “UpCell”, is the essential technology needed for generating cell sheets, enabling the conversion from cells to tissue. Our clinical focus is currently within knee cartilage regenerations, esophageal regenerations and corneal regenerations.
As an overseas business development, CellSeed is also expanding its activities in EU through its subsidiary, CellSeed Sweden AB, North America region and Asia Pacific region. In April 2017, CellSeed executed the contract with MetaTech AP Inc., Taiwan for licensing products.
We are looking for collaborative business or licensing partners for our 'Cell Sheet' regenerative medicine platform technology, especially our ATMP pipeline, both regionally and globally.